FDA Grants Accelerated Approval to Telisotuzumab vedotin-tllv for NSCLC

Source: Pharmacy Times articles

Emrelis is a groundbreaking treatment for advanced non-small cell lung cancer, targeting high c-Met protein overexpression.
Read More